Online citations, reference lists, and bibliographies.
← Back to Search

Novel Amphiphilic Carriers: One Step Further In Cancer Management

M. Misran
Published 2016 · Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
The ideal goal of treatment, and most often the goal in practice, is the successful removal of cancer with near-zero damage to the rest of the body. As cancer is referred to a class of disease, it is unlikely to idealize a single cure for cancer. The attempt to cure cancer has been revolutionized over decades as the underlying processes have revealed more horizons of understanding. Although a number of strategies have been developed, the associated side effects have led the research to enter a new era of nanoengineering and nanotechnology. Designing versatile nanocarriers offer efficient drug delivery applications with enhanced therapeutic benefits of drug. Amphiphilic nanocarriers fall under the heading of such novel carriers which offer high circulation half-life, low risk to benefit ratio of drugs, sustained release and effective targeting. They provide a paradigm for the design of nanocarriers with a broad spectrum of functionality, applicability, and versatility of synthetic drug delivery particles.
This paper references
Nanomedicine in Cardiovascular
C Psarros (2016)
10.1016/S0168-3659(03)00215-3
Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospects.
Y. Lu (2003)
10.1039/c5nr02247a
A redox-responsive mesoporous silica nanoparticle capped with amphiphilic peptides by self-assembly for cancer targeting drug delivery.
D. Xiao (2015)
10.1016/S0167-4889(02)00256-2
Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis.
U. Nielsen (2002)
10.1016/J.ADDR.2004.12.005
Water insoluble and soluble lipids for gene delivery.
R. Mahato (2005)
10.1017/S1462399499001099X
Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs.
M. Links (1999)
10.1093/cvr/cvv037
Phosphatidylserine liposomes mimic apoptotic cells to attenuate atherosclerosis by expanding polyreactive IgM producing B1a lymphocytes.
H. Hosseini (2015)
10.1016/J.ADDR.2004.02.014
Nanoparticle and targeted systems for cancer therapy.
L. Brannon-Peppas (2004)
10.1039/c3nr03064d
Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles.
R. Fang (2013)
10.1021/AM300992X
Nanosize and surface charge effects of hydroxyapatite nanoparticles on red blood cell suspensions.
Y. Han (2012)
10.1016/j.addr.2016.01.009
"Eat me" imaging and therapy.
Vaishali Bagalkot (2016)
10.1073/pnas.0907127106
Red blood cell-mimicking synthetic biomaterial particles
N. Doshi (2009)
10.1021/acsnano.6b00261
Exploring Cellular Interactions of Liposomes Using Protein Corona Fingerprints and Physicochemical Properties.
A. Bigdeli (2016)
10.1023/A:1025785505977
Drug Delivery and Transport to Solid Tumors
S. H. Jang (2004)
10.1016/j.urolonc.2007.03.015
Nanoparticles for drug delivery in cancer treatment.
B. Haley (2008)
10.1371/journal.pone.0057136
Permeation of Insulin, Calcitonin and Exenatide across Caco-2 Monolayers: Measurement Using a Rapid, 3-Day System
V. Gupta (2013)
Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation
다츠히로 이시다 (2009)
10.1002/dta.1956
Liposomes as potential masking agents in sport doping. Part 2: Detection of liposome-entrapped haemoglobin by flow cytofluorimetry.
S. Esposito (2017)
10.1002/dta.1939
Liposomes as potential masking agents in sport doping. Part 1: analysis of phospholipids and sphingomyelins in drugs and biological fluids by aqueous normal-phase liquid chromatography-tandem mass spectrometry.
S. Esposito (2017)
10.1021/am4045713
Mimicking red blood cell lipid membrane to enhance the hemocompatibility of large-pore mesoporous silica.
R. Roggers (2014)
10.1006/BBRC.1999.0177
Toward selection of internalizing antibodies from phage libraries.
B. Becerril (1999)
10.1016/S0168-3659(97)00237-X
Delivery of molecular and cellular medicine to solid tumors.
Jain (1997)
Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.
A. Eberhard (2000)
10.1074/jbc.R114.617951
G Protein-coupled Receptor (GPCR) Signaling via Heterotrimeric G Proteins from Endosomes*
Nikoleta G. Tsvetanova (2015)
10.1021/bc100070g
Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects.
H. Maeda (2010)
10.1021/acsami.5b05038
Self-Assembled Nanoparticles Based on Amphiphilic Anticancer Drug-Phospholipid Complex for Targeted Drug Delivery and Intracellular Dual-Controlled Release.
Y. Li (2015)
10.1208/s12248-014-9687-3
Strategic Approaches to Optimizing Peptide ADME Properties
Li Di (2014)
10.1016/j.jconrel.2016.02.019
Liposomal nanocarriers for plasminogen activators.
Štěpán Koudelka (2016)
10.1016/S0169-409X(98)00003-9
Control of tumour vascular permeability.
Baban (1998)
Nanomedicine in Cardiovascular. Nanotechnology and Drug Delivery, Volume Two: Nano-Engineering Strategies and Nanomedicines against Severe Diseases: 257
C Psarros (2016)
Bin Misran M (2015) Drug delivery and innovative pharmaceutical development in mimicking the red blood cell membrane
S Naeem
Liposomal [Beta]Glucan: Preparation, Characterization and Anticancer Activities
M Halwani (2015)
10.1177/153303460500400405
Targeted Drug Delivery in Cancer Therapy
Jaspreet K. Vasir (2005)
Maiseyeu A (2016) “Eat me” imaging and therapy
V Bagalkot (2016)
10.1016/j.addr.2012.09.037
Liposomal drug delivery systems: from concept to clinical applications.
T. Allen (2013)
10.1016/S0378-5173(03)00128-5
Development of polymeric nanoparticulate drug delivery systems: evaluation of nanoparticles based on biotinylated poly(ethylene glycol) with sugar moiety.
I. Kim (2003)
10.1007/978-1-4939-3121-7_23
Cancer Therapy with Nanotechnology-Based Drug Delivery Systems: Applications and Challenges of Liposome Technologies for Advanced Cancer Therapy
R. Suzuki (2016)
Liposome: Emerging Trends In Transdermal Drug Delivery
N Thakur (2016)
10.1042/BST20150230
From biased signalling to polypharmacology: unlocking unique intracellular signalling using pepducins.
R. Carr (2016)
10.1515/revce-2015-0010
Drug delivery and innovative pharmaceutical development in mimicking the red blood cell membrane
Sumaira Naeem (2015)
10.1039/C6TB00344C
Expedient synthesis of functional single-component glycoliposomes using thiol-yne chemistry.
D. Goyard (2016)



Semantic Scholar Logo Some data provided by SemanticScholar